HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells

Prolonged treatment of HER2 positive breast cancer cells with tyrosine kinase inhibitors (TKIs) leads to the emergence of acquired resistance. However, the effects of continuous TKI exposure on cell fate, and the steps leading to the acquisition of a resistant phenotype are poorly understood. To exp...

Descripción completa

Detalles Bibliográficos
Autores principales: McDermott, Martina S. J., Conlon, Neil, Browne, Brigid C., Szabo, Adam, Synnott, Naoise C., O’Brien, Neil A., Duffy, Michael J., Crown, John, O’Donovan, Norma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406301/
https://www.ncbi.nlm.nih.gov/pubmed/30743996
http://dx.doi.org/10.3390/cancers11020197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406301/
https://www.ncbi.nlm.nih.gov/pubmed/30743996
http://dx.doi.org/10.3390/cancers11020197

Ejemplares similares